FRANKFURT (Reuters) - German drugmaker Bayer said it filed for marketing approval in Europe for the use of eye drug Eylea as a treatment of diabetic macular oedema.
Bayer has said it expects Eylea, also known as VEGF Trap-Eye, to generate more than 1 billion euros ($1.35 billion) in peak annual sales.
The injection, which Bayer is co-developing with Regeneron, is already approved for other eye diseases. ($1 = 0.7392 euros)
(Reporting by Ludwig Burger; Editing by Christoph Steitz)